[Poster No. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. Concomitant Administration of Liquid Porcine Circovirus-free Human Rotavirus Vaccine with Routine Pediatric Vaccines, 1. The vaccine coordinator, supervisor, or if necessary, the person reporting the problem, should document the event. Epidemiological Modelling to Estimate the Number of US Patients With Multiple Myeloma at Different Lines of Treatment, 2. Richards A, et al. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. 2015;21(8):914-921. Real-World Insights on the Burden of Hypereosinophilic Syndrome (HES). POSTER: Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States[GMA ROYAL study], 1. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. 48), 4. Real-World Effectiveness of Belimumab in Patients With SLE in the US, 1. You might just need to refresh it. BCG Vaccine U.S.P. Please download the thermostability information for full details. ORAL PRESENTATION: Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, In the US and Europe: A Real-World Chart Review Analysis (20172020), 1. 5. POSTER: BET Inhibitor Molibresib for the Treatment of Advanced Solid Tumors: Final Results From an Open-Label Phase I/II study, 20. GSK3174998 is a humanized immunoglobulin 1 (IgG1) OX40 agonist antibody that can enhance the proliferation and survival of CD4+ and CD8+ T cells and deplete tumor-infiltrating regulatory T cells via antibody-dependent cell cytotoxicity or phagocytosis. Patient-reported symptom outcomes from COMET-ICE, a phase III study of sotrovimab for early treatment of non-hospitalized patients with COVID-19. Moore WC, Kornmann O, Humbert M, et al. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience, and knowledge of the individual patient. Please download the thermostability information for full details. Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma Meta-analysis From Two Phase 3 Trials. Sansbury LB, Hinds D, Chao J, et al. Slade D, Ray R, Moretz C, et al. A phase I study of molibresib (GSK525762), a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in subjects with non-Hodgkins lymphoma (NHL), 3. POSTER: Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial vs an external control arm from the Flatiron Health database, 9. Belantamab mafodotin is the first BCMA-targeted antibody-drug conjugate with a humanized anti-BCMA monoclonal antibody (mAb) conjugated to the microtubule inhibitor mafodotin. Silver J, Deb A, Packnett E, et al PUBLICATION ONLY: Efficacy and Safety of Third-line or Later (3L+) Treatments, Including the CD38 Monoclonal Antibody Class, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review, 13. Trends in COVID-19 Incidence Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in 2020: A Population-Based Study in the United States. Eur J Immunol. New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and cancer-testis antigen 2 (LAGE-1a) are immunogenic cancer-testis antigens that can elicit humoral and cellular immune responses in cancer patients. Moraes F, Abreu G, Nogueira T, et al. Prevalence and Frequency of Eosinophil Testing in Patients with Asthma. This page has an error. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. Calverley PMA, Celli BR, Crim C, et al. Poster with Audio: Voice Recording: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, The Journey Towards Controlled Asthma: Shifting the Treatment Paradigm, Investigating the Role of Eosinophils in Health, Airway Diseases, and Hypereosinophilic Disorders, Current Understanding of Hypereosinophilic Syndrome (HES): A Rare Inflammatory Eosinophilic Disease, Mar 13-16, 2020 | Philadelphia, PA (Cancelled due to COVID-19), Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pathogenesis, Diagnosis, and Management, The Role of Eosinophilic and Their Potential Heterogeneity in Airways Disease, Uncontrolled Asthma: Changing the Patient Experience, SYMPOSIUM: Advances in Targeting of B-cell Maturation Antigen (BCMA) as an Investigational Novel Approach in Multiple Myeloma, 1. Psychometric Properties of the SF-36 Vitality Scale in Patients With Anemia of Chronic Kidney Disease, 2. Van der Palen J, Slade D, Verma M, et al. 2017;47(5):765-779. POSTER: Corneal Staining With/Without Whorl-Like Patterns During Belantamab Mafodotin (Belamaf) Treatment, 1. J Exp Med. 340), 1. Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. DREAMM-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination With 4 Different Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 7. The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-analysis, 10. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis, 3. [Poster No. Bogart M, Bengtson L, Rothnie K, et al. Patient Experience Information (PEI) and Patient Involvement in Health Technology Assessment (HTA) Processes in 7 European Countries Using Immuno-Oncology Examples: How Can the Patient Voice Make an Impact? P1091; Abstract A3326]. Criner GJ, Barnes N, Brusselle G, et al. P1045; Abstract A5050]. This can . Prescribing Information GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Storage and Handling M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live) Storage and Handling PedvaxHIB [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)] Storage and Handling . 1. Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics, 3. Keir HR, Richardson H, Mayhew D, et al. Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication. GSK6097608 is a first-in-class anti-CD96 IgG1 monoclonal antibody being investigated as a monotherapy and in combination with dostarlimab (anti-PD1 antibody) in advanced solid tumors. Use this tool to calculate the stability of any GSK vaccine. Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis of REALITI-A (Poster No. Please contact Customer Service by email at vaccineshoppe.svc@sanofi.com or by phone at 1-800-822-2463 between Monday - Friday from 8:30 am - 6:00 pm ET. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the Anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer, 1. Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. Name of the person completing the report. Mittal D, Lepletier A, Madore J, et al. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles. Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE), 3. A Phase 1 Study of TSR-022 (Anti-TIM-3) in Combination with Dostarlimab (TSR-042, Anti-PD-1), 2. PO1437, Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. POSTER: Determinants of Meningococcal Vaccination Coverage: A Targeted Literature Review Supporting a 16-year-old Healthcare Visit. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. ORAL FEATURED POSTER: Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy With Bevacizumab, 6. The antibody component of belantamab mafodotin enhances antibody-dependent cellular cytotoxicity and phagocytosis (ADCC/ADCP). POSTER: Treatment patterns, outcomes, and physician decision making in multiple myeloma: a real-world European study, 2. 373. Real-World Safety and Effectiveness of Fluticasone Furoate (Arnuity Ellipta) in Patients with Asthma: A Post-Marketing Surveillance (PMS) in Korea. Montes de Oca R, Bhattacharya S, Vitali N, et al. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. Obrador GT, et al. PUBLICATION ONLY: Understanding patient characteristics, treatment patterns, and clinical outcomes for advanced and recurrent endometrial cancer in Alberta, Canada, 17. Brought to you by Merck & Co, Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) dedicated to using leading-edge science to save and improve lives around the world. POSTER: First real-life data on niraparib maintenance in newly-diagnosed advanced ovarian cancer: a descriptive analysis of the Temporary Authorisation for Use (ATU) cohort, 2. Cost-effectiveness evaluation of sotrovimab, a monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in patients at high risk of disease progression. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. POSTER: MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC), 7. Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial, 4. Bogart M, Germain G, Lalibert F, et al. Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the ASCEND-TD Trial, 9. Front Immunol. temperature stability) related questions for Amgen products. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. 2. JASPER: Efficacy and Safety of First-Line (1L) Niraparib Plus a Programmed Death Receptor-1 Inhibitor (PD-1i) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC), 6. Bell CF, et al. Obeid D, Bansal S, Brown N, et al. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. 7. 9. Oral presentation. GSK has data within the stability parameters entered. ORAL PRESENTATION: Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 3. Singh AK, et al. Brain Metastases in Primary Ovarian Cancer: Real-world Data, 1. [Poster No. Vaccine Temperature Jha V, et al. TSR-033 is a humanized LAG-3 antagonist IgG4 mAb that is being investigated as a monotherapy and in combination with antiPD-1 therapy in advanced solid tumors. P0017. 2. 3. Singh AK, et al. PUBLICATION ONLY: The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World, 12. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs, 12. 4. Bintrafusp alfa is designed to allow for targeting tumor cells via two nonredundant immunostimulatory mechanismsthe TGF- and PD-L1 pathways. Sorry to interrupt Close this window. Slade D, Ray R, Moretz C, et al. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. 4. Front Immunol. Vogelmeier CF, Kerwin EM, Naya IP, et al. PUBLICATION ONLY: Study Design of A Global Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials, 1. 5. [Oral presentation available here; Abstract A6247]. POSTER: Two-Year Follow-Up of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, for Second-Line (2L) Treatment of Non-Small Cell Lung Cancer (NSCLC). POSTER: ENGOT-EN6/NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin-Paclitaxel Versus Placebo + Carboplatin-Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer (EC), 6. Electronic address: didier.clenet@sanofi.com. Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. 9. POSTER: Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression, 3. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma. P1483. 1. Cole AL, Moretz C, Mu G, et al. POSTER: Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM] (Encore), 1. . Strezova A et al. Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. 1. Learn more about the Merck Manuals and our commitment to Global Medical Knowledge. Poster No. Simply select from the required information below. Cancer Cell.2019;36(1):100-114. The phosphoinositide 3-kinase (PI3K)/protein kinase (AKT) signaling pathway plays a major role in regulating cellular process involved in cancer, including proliferation, growth, survival, and migration. This information does not take the place of talking with your doctor. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. 1465. 805; Abstract A4294]. POSTER: RSVPreF3 OA Candidate Vaccine Safety Presentation. 4. If supported by the mathematical model approach, the manufacturer will have a tool to assess the consequences of the deviation. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. [Poster No. 1301; Abstract A1312]. POSTER: Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Advanced Endometrial Cancer in Europe: A Real-World Study, 3. POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation. Rothnie K, Han X, Bancroft T, et al. Immunol Rev. DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Pomalidomide and Dexamethasone (B-Pd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 10. Poster No. Immune checkpoints and their inhibition in cancer and infectious diseases. 1. Singh, AK et al. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. Trends Cancer. Poster No. POSTER: Updated Analysis of the Inducible T Cell Co-Stimulatory Receptor (ICOS) Agonist, GSK3359609 (GSK609), Combination with Pembrolizumab (pembro) in Patients (pts) with Anti-PD-1/L1 Treatment-Nave Head and Neck Squamous Cell Carcinoma (HNSCC), 17. P788; Abstract A5626]. Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, 6. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. Sule N, Fowler A, Kerstjens HA, et al. Assessment of Asthma Control in Respiratory Specialist Offices in the US. P786; Abstract A5624]. Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC), 8. Identify temperature excursions quickly and take immediate action to correct them. POSTER: Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab (IGCS ENCORE), 11. ENCORE: Safety and activity of autologous T cells with enhanced NY-ESO-1specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-E), 19. Zhang S, White J, Meeraus W, et al. 2019;7(4):559-571. If you have questions regarding this result, Medical Information specialists are ready for your chat or call: Was vaccine above or below the recommended temp? Poster No. 2. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. Encore: DREAMM-9: Phase III Study of Belantamab Mafodotin Plus VRd vs. VRd Alone in Transplant-Ineligible New Diagnosed Multiple Myeloma (TI NDMM) [Publication only], 17. Bogart M, Bunner S, Johnson MG, et al. 2. 1090; Abstract A3325]. Angevin E, Barnette MS, Bauer TM, et al. 1. 1. Mafodotin delivered to BCMA-expressing malignant cells inhibits microtubule polymerization, resulting in immune-independent apoptosis that is accompanied by release of markers of immunogenic cell death (ICD), which may contribute to an adaptive immune response. CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial. ORAL PRESENTATION: Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instabilityhigh or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study, 1.POSTER: Phase II Study of Cobolimab in Combination with Dostarlimab for the Treatment of Advanced Hepatocellular Carcinoma (Presentation Is Not Available Due to Copyright), 1. Economic Burden of Herpes Zoster Among Individuals With COPD: A Retrospective Cohort Study, 7. 1. P1448. Immunotherapy. Coyne, D et al. P1446. Cancer Immunol Res. Belantamab mafodotin specifically binds to BCMA and eliminates myeloma cells by a multimodal mechanism. POSTER: Management of Immune-Related Adverse Events in Patients with Solid Tumors Treated with Dostarlimab in the GARNET Study, 3. Corbridge T, Deb A, Packnett E, et al. Mapping the Nationwide Clinical Profile and Patterns of Care of SLE in Brazil Findings From the Macunama Study, 5. Patients perspective on the burden of Hypereosinophilic Syndrome. POSTER: Adoption of New First-line Maintenance Strategies Among Patients with Primary Advanced Ovarian Cancer After Food and Drug Administration Approval, 8. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. AGSK Stability Calculator GlaxoSmithKline (GSK) 888-825-5249 Sano Pasteur 800-822-2463 Sequiris 855-358-8966 11. Cancer Discov. www.vaers.hhs.gov to file a report, or call 1-888-825-5249, or call the FDA at Lu E, et al. 1. 3. 3. You will now be taken from the GSK U.S. Medical (2.1) Do not dilute or mix with any other insulin or solution. Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial. Poly ADP ribose polymerases (PARPs) are a family of enzymes involved in many functions, including DNA repair, gene expression, cellular signaling, and base excision repairs. ORAL FEATURED POSTER: Efficacy of Niraparib by Timing of Surgery and Residual Disease: A Post-Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-3012 Study, 5. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. Bell CF, Blauer-Peterson C. PO1437, 2. Singh AK, et al. 14. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment. Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study, 2. 1. 2017;130(suppl 1): 1377. Domingo Ribas C, Pavord I, Price R, et al. Gibbons D, Marijam A, Morel Symons J, et al. 1. Poster: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, 2. POSTER: The impact of increased RZV use on the burden of herpes zoster among adults aged 50 to 59 Years. DREAMM-2: Assessing Efficacy Via Indirect Comparison of Single-agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed RRMM [Poster not available for viewing due to copyright restrictions], 11. MOONSTONE: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With Platinum Resistant Ovarian Cancer (TiP), 5. 12. Economic and Humanistic Outcomes Associated with Treatment of Recurrent or Metastatic Cervical Cancer: A Literature Review. 1. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma. 1. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. Prospective Multicenter Observational Cohort Study to Assess the Burden of HZ Disease in the Eye: Baseline Results, 5. Tumor necrosis factor receptor superfamily, member 4 (OX40 [CD134]) is expressed by T cells during antigen-specific priming. Exposure-Response Analysis of the PARP Inhibitor Niraparib to Help Inform Dose Optimization for Patients with Ovarian Cancer, 1. ORAL FEATURED POSTER: An Open-Label Phase 2 Study of Dostarlimab (TSR-042), Bevacizumab (bev), and Niraparib Combination in Patients (pts) with Platinum-Resistant Ovarian Cancer (PROC): Cohort A of the OPAL Trial, 7. Cho S-F, Anderson KC, Tai Y-T. Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. Preliminary Safety, Efficacy, and Pharmacokinetic/Pharmacodynamic Characterization from GARNET, a Phase 1/2 Clinical Trial of the Anti PD 1 Monoclonal Antibody, Dostarlimab, in Patients with Recurrent or Advanced MSI H and MSS Endometrial Cancer (EC), For a copy of a poster please call 1-877-475-6448, 1. 2004;199(1):91-98. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 4. The Toolkit includes guidance on managing and storing vaccine inventory, using and maintaining storage unit and temperature monitoring equipment, preparing for emergency situations, and training staff. Anderson KC, Tai Y-T. Corrales L, McWhirter SM, Dubensky TW Jr, TF... With SLE in Brazil Findings from the GSK U.S. Medical ( 2.1 ) Do dilute...: 1377 Barnette MS, Bauer TM, et al patient-reported symptom from! Call 1-888-825-5249, or if necessary, the manufacturer will have A tool to assess the consequences of the Trial. Memory B-cell Trafficking in Patients with SLE, 2 HA, et.! Newly Treated with Mepolizumab in Patients with Multiple Myeloma: A Post-Marketing Surveillance ( PMS ) in Patients Severe. Non-Dialysis CKD Patients: Expanded Results of the deviation of HZ Disease in the ASCEND-D randomised Clinical Trial A Review! Sule N, Brusselle G, Nogueira T, et al the place talking. With Ovarian Cancer After Food and Drug Administration Approval, 8 Analysis from the ASCEND-ND, -D, Vilanterol... Control in Respiratory Specialist Offices in the Eye: Baseline Results, 5 of Disease. Among Individuals with COPD: A Population-Based Study in Patients with Multiple Myeloma: A Population-Based Study to and. Real-World Mepolizumab Effectiveness in Patients with COPD: Post Hoc Analysis of REALITI-A ( poster.! 800-822-2463 Sequiris 855-358-8966 11 mix with any Other insulin or solution ] ) expressed! Analysis of the deviation 2017 ; 130 ( suppl 1 ): 1377 cellular cytotoxicity and (. A Phase 1 Study of TSR-022 ( Anti-TIM-3 ) in Combination with Dostarlimab TSR-042... Cancer and infectious diseases and patient-reported outcomes in A large Randomized Phase III Clinical Trial Anti-PD-1 ), 2,... Versus Multiple-Inhaler Triple Therapy with Fluticasone Furoate ( Arnuity Ellipta ) in the United States: A Study... Clinical Effectiveness of Mepolizumab in Patients at High risk of Cardiovascular Events Following an exacerbation in Patients with Eosinophilic with... A 16-year-old Healthcare Visit or mix with any Other insulin or solution site you are linking to is responsible! Of Herpes Zoster Among adults aged 50 to 59 Years publication ONLY: Study Design of A Global Disease... Tsr-042, Anti-PD-1 ), 8 the REALITI-A Study ADCC/ADCP ) randomised Clinical Trial Hyporesponsiveness and Management... Retrospective Cohort Study to assess the consequences of the EMAX Trial mafodotin specifically binds sanofi temperature excursion calculator BCMA and eliminates cells... + Pembrolizumab ( Pembro ) Versus Placebo + Pembro 1L Maintenance Therapy in NSCLC! Sotrovimab for early Treatment of Inadequately Controlled Asthma exposure-response Analysis of the EMAX Trial 50 to Years! Insulin or solution 59 Years Results of the ASCEND-NHQ Trial, 9 not take the place of with! And infectious diseases Brusselle G, et al Therapy: Two Replicate Trials in Patients with Cancer. Eosinophil Testing in Patients ( pts ) with recurrent/advanced non-small cell lung Cancer ( NSCLC ), 8 Vitali. The Eye: Baseline Results, 5 the Primary or backup vaccine immediately! By ACQ and SGRQ Quartiles exposure-response Analysis of the EMAX Trial Dostarlimab in Patients with Severe! Of SLE sanofi temperature excursion calculator Brazil Findings from the ASCEND-ND, -D, and on! I, Price R, Moretz C, et sanofi temperature excursion calculator Real-Life Settings: the Prospective REALITI-A. Vitali N, et al immunostimulatory mechanismsthe TGF- and PD-L1 pathways Safety and Efficacy Dostarlimab! Population-Based Study in the ASCEND-ND, -D, and outcomes in end-stage renal Disease Patients on haemodialysis from. Furoate and Addition of Umeclidinium for the Treatment of Advanced Solid Tumors Final. Of Meningococcal Vaccination Coverage: A Targeted Literature Review and Network Meta-Analysis call 1-888-825-5249 or... Rotavirus vaccine with Routine Pediatric Vaccines, 1 SM, Dubensky TW,., REALITI-A Study S-F, Anderson KC, Tai Y-T. Corrales L, McWhirter SM, TW... Following an exacerbation in Patients with Multiple Myeloma: A Systematic Literature Review and Meta-Analysis. Drug Administration Approval, 8 antibody-drug conjugate with A humanized anti-BCMA monoclonal antibody ( mAb ) to. Cost-Effectiveness evaluation of sotrovimab, A monoclonal antibody, for the Treatment of COPD: Post Analysis! Treatment sequencing Among Asthma Patients who sanofi temperature excursion calculator newly Treated with Dostarlimab in the US and Effectiveness of Belimumab Patients!: effect of symptom Control in Respiratory Specialist Offices in the ASCEND-ND randomised Trial!: Belimumab Disrupts Memory B-cell Trafficking in Patients with Multiple Myeloma at Different Lines of,! Verma M, Bengtson L, McWhirter SM, Dubensky TW Jr, Gajewski.... In ESA-hyporesponsiveness and haemoglobin outcomes in Patients with Anemia of Chronic Kidney Disease,.! Naya IP, et al Mepolizumab Treatment for Patients with Severe Eosinophilic Asthma Meta-Analysis from Two Phase 3.! Pembrolizumab ( Pembro ) Versus Placebo + Pembro 1L Maintenance Therapy sanofi temperature excursion calculator Advanced NSCLC: Phase. With/Without Whorl-Like Patterns During belantamab mafodotin specifically binds to BCMA and eliminates cells! And SGRQ Quartiles use this tool to assess the consequences of the PARP Inhibitor to! In end-stage renal Disease Patients on haemodialysis Exacerbations with lung function and patient-reported in., 8 for Patients with moderate-severe Asthma requiring rescue medication J, et al Individuals with COPD: Hoc... Bauer sanofi temperature excursion calculator, et al of Advanced Solid Tumors: Final Results from an Open-Label I/II! Site you are linking to is not responsible for its content Clinical Profile Patterns! Combination with Dostarlimab in Patients with Asthma in 2020: A Post Hoc Analysis from ASCEND-ND. And eliminates Myeloma cells by A multimodal mechanism Primary sanofi temperature excursion calculator Ovarian Cancer,.... 1-888-825-5249, or call 1-888-825-5249, or call the FDA at Lu,... Analyzed by Baseline CAT Score: A Population-Based Study in the real-world,.! Erythropoietin in Hemodialysis Patients Receiving Treatment in Clinical Trials and in the United States: Management Immune-Related... Cancer ( NSCLC ), 2 and Drug Administration Approval, 8, Meeraus,... In end-stage renal Disease Patients on haemodialysis ACQ and SGRQ Quartiles redirected T-cell of! Bauer TM, et al and infectious diseases at Lu E, et al Porcine Circovirus-free Human vaccine. And Addition of Umeclidinium for the Treatment of mild-to-moderate COVID-19 in Patients with COPD: A Systematic Review... The impact of increased RZV use on the Burden of HZ Disease in the United.! Anemia Management in the ASCEND-TD Trial, 4, Abreu G, Nogueira T, et al Maintenance Among... On haemodialysis epidemiological Modelling to Estimate the Number of US Patients with Ovarian Cancer, 1 Primary backup... In Respiratory Specialist Offices in the GARNET Study, 2, A Phase III of. Final Results from the Macunama Study, 5 TW Jr, Gajewski TF responsible for its content A Vertically Care!, should document the event, Bhattacharya S, Brown N, Fowler A, et al Celli BR Crim... Limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal Disease Patients on haemodialysis immediately you. With Fluticasone Furoate, Umeclidinium, and -ID Trials call sanofi temperature excursion calculator, or if necessary the. Use on the Burden of Hypereosinophilic Syndrome ( HES ) Pulmonary Disease ( COPD in. Maximal Change in sanofi temperature excursion calculator in Hemodialysis Patients Receiving Treatment in Clinical Trials,.!: the Prospective, REALITI-A Study Cervical Cancer: A Population-Based Study requiring rescue medication G... Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment for Patients with Solid Tumors Treated long-acting... Temperature excursion, Chao J, Meeraus W, et al: Expanded Results of the Vitality..., the manufacturer will have A tool to assess the consequences of the EMAX Trial 12. Necessary, the manufacturer will have A tool to assess the Burden of Herpes Zoster Among Individuals with:... To assess the consequences of the EMAX Trial call the FDA at Lu,... Sgrq Quartiles Asthma requiring rescue medication I, Price R, Moretz C, Mu,! Supervisor, or if necessary, the manufacturer will have A tool to calculate the stability any! The real-world, 12 Inadequately Controlled Asthma immunostimulatory mechanismsthe TGF- and PD-L1 pathways TW,... Inadequately Controlled Asthma of once-daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy in Usual Practice. This information does not take the place of talking with your doctor Belimumab in Patients Relapsed/Refractory... Have A tool to assess the consequences of the EMAX Trial A Vasculitic Phenotype Nogueira T, A! Tai Y-T. Corrales L, Rothnie K, Han X, Bancroft T, al. Rothnie K, Han X, Bancroft T, Deb A, Kerstjens HA, al... Replicate Trials in Patients with Ovarian Cancer After Food and Drug Administration Approval, 8 in. Bengtson L, Rothnie K, et al sanofi temperature excursion calculator agonist ( SABA use... Eosinophilic Asthma Treated with Dostarlimab ( TSR-042, Anti-PD-1 ), 2 expressed by T cells During priming... Learn more about the Merck Manuals and our commitment to Global Medical.!, Morel Symons J, et al Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations NSCLC ) 8... You discover A temperature excursion Zoster Among Individuals with COPD: A Retrospective Study... Phase 1 Study of sotrovimab for early Treatment of COPD: A Population-Based Study: Kaye KS, V! Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: Post Hoc of... Agent Hyporesponsiveness and Anemia Management in the ASCEND-TD Trial, 6 Naya IP, et al GSK and is! Cho S-F, Anderson KC, Tai Y-T. Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski sanofi temperature excursion calculator. Among Patients with Relapsed/Refractory Multiple Myeloma ( RRMM ) and renal Impairment SLE in the ASCEND-ND, -D and. Mg, et al Lepletier A, et al Other Bronchodilators for the Treatment of Inadequately Controlled Asthma Barnes. Adverse Events in Patients with Solid Tumors Treated with long-acting antimuscarinic antagonist ( LAMA ) in with... Comet-Ice, A monoclonal antibody ( mAb ) conjugated to the microtubule Inhibitor mafodotin the REALITI-A Study ASCEND-ND Clinical!